Guideline of guidelines: lutetium‐177 PSMA radioligand therapy in advanced prostate cancer

Key Points

• To evaluate the current guidelines for patient selection, dosing, and implementation of PSMA-RLT in advanced prostate cancer.
• Review of international guidelines on PSMA-RLT.
• Analysis of ongoing trials such as PSMAfore and UpFrontPSMA.
• Assessment of multidisciplinary approaches in treatment settings.
• Guidelines emphasize the importance of patient selection and proper dosing.
• Ongoing trials are expected to clarify the role of PSMA-RLT in earlier treatment stages.
• Evidence suggests positive outcomes with combination therapies.